– Natural Hall Global Holdings Limited (自然堂全球控股有限公司) has filed for a Hong Kong IPO, positioning itself as China’s third-largest domestic cosmetics group by 2024 retail sales, yet growth is slowing amid profitability volatility.
– The company exhibits a severe imbalance between marketing and R&D expenditures, with 2024 marketing costs at 29.9 times R&D spending, raising doubts about its ‘tech beauty’ branding claims.
– Recent controversies involving global skincare spokesperson Yu Shuxin (虞书欣) highlight the risks of over-reliance on celebrity endorsements, potentially impacting brand reputation during the IPO process.
– Family control remains absolute, with the Zheng family holding approximately 87.82% voting power, prompting governance concerns despite pre-IPO investments from L’Oréal and Jiahua Capital.
– Consumer complaints on third-party platforms, including过敏 (allergy) issues, underscore product safety challenges that could affect long-term brand equity and investor confidence.
Natural Hall’s IPO: A Pivotal Moment in China’s Beauty Market
Natural Hall Global Holdings Limited (自然堂全球控股有限公司), a 24-year-old domestic cosmetics brand, has officially submitted its listing application to the Hong Kong Stock Exchange, marking a critical step in its capital market journey. The Natural Hall IPO comes at a time when Chinese beauty brands are gaining global traction, but it also exposes underlying vulnerabilities in its business model. With retail sales ranking it as China’s third-largest domestic cosmetics group in 2024, the company’s debut is closely watched by institutional investors seeking exposure to China’s consumer sector. However, the Natural Hall IPO must navigate significant headwinds, including familial dominance, skewed resource allocation, and reputational risks tied to marketing strategies.
Financial Performance and Market Positioning
Natural Hall’s revenue growth has shown signs of deceleration, with 2022 to 2024 figures of 4.292 billion yuan, 4.442 billion yuan, and 4.601 billion yuan, respectively, translating to a 3.5% year-on-year increase in 2024. The first half of 2025 recorded revenue of 2.448 billion yuan, up 6.43% from the previous year. While these numbers indicate stability, they lag behind peers like Proya (珀莱雅), which saw a 21% revenue surge in 2024, and Shanghai Jiahua (上美股份), with a 62.1% growth rate, suggesting weaker momentum for the Natural Hall IPO.
Profitability and Margin Analysis
Net profit volatility is a red flag, with figures of 139 million yuan in 2022, 302 million yuan in 2023, and 190 million yuan in 2024, reflecting a 117% jump in 2023 followed by a 37.1% drop in 2024. Gross margins improved from 66.5% in 2022 to 70.1% in H1 2025, yet net margins remained unstable at 3.2%, 6.8%, 4.1%, and 7.8% over the same period. This inconsistency stems from high operational costs, particularly in sales and marketing, which consumed over 50% of revenue annually. The Natural Hall IPO must address these profitability swings to attract discerning investors.
The R&D and Marketing Imbalance
A core issue for the Natural Hall IPO is the stark contrast between its marketing and R&D expenditures. From 2022 to H1 2025, cumulative R&D spending totaled just 348 million yuan, a mere 13% of the 2024 marketing outlay alone. Marketing expenses consistently exceeded 50% of revenue, peaking at 59% in 2024, compared to R&D rates declining from 2.8% in 2022 to 1.7% in H1 2025. This disparity challenges the company’s ‘tech beauty’ positioning and could deter investors seeking innovation-driven growth in the Natural Hall IPO.
Comparative Industry Benchmarks
– Proya (珀莱雅): 2024 R&D spending of 210 million yuan, with marketing-to-R&D ratio of 24.6 times.
– Shanghai Jiahua (上海家化): R&D investment of 150 million yuan, ratio of 17.6 times.
– Betaine (贝泰妮): R&D expenditure of 295 million yuan, ratio of 9.7 times.
Natural Hall’s 2024 marketing-to-R&D ratio of 29.9 times exceeds all these peers, highlighting a structural weakness. The Natural Hall IPO prospectus emphasizes technological advancement, but the data reveals a prioritization of short-term sales over long-term research, potentially undermining competitive advantage.
Celebrity Endorsement Risks and Consumer Feedback
The Natural Hall IPO faces heightened scrutiny due to its heavy reliance on celebrity endorsements, exemplified by the controversy involving global skincare spokesperson Yu Shuxin (虞书欣). Reports from financial blogger ‘Old Pan Finance’ alleged that Yu’s father, Yu Moujie (虞某杰), misused 1.5 billion yuan in state-owned enterprise funds through affiliated companies, raising tax evasion concerns. Although Yu’s studio denied wrongdoing, the incident led Natural Hall to postpone a live-streaming event and reduce related promotional content, illustrating the ‘endorser risk’ inherent in its strategy.
Product Safety and Consumer Complaints
Family Control and Corporate GovernanceThe Zheng family, comprising siblings Zheng Chunying (郑春颖), Zheng Chunbin (郑春彬), Zheng Chunwei (郑春威), and Zheng Xiaodan (郑小丹), controls approximately 87.82% of voting rights through offshore entities and direct holdings. Zheng Chunying (郑春颖), founder and CEO, drives the company’s vision, while his siblings hold executive and non-executive director roles. This concentration of power, common in founder-led firms, raises governance questions for the Natural Hall IPO, particularly regarding minority shareholder protections.
Pre-IPO Investments and Valuation
To bolster its appeal, Natural Hall secured 442 million yuan from L’Oréal’s subsidiary, Meiting (美町), for a 6.67% stake, and 300 million yuan from Jiahua Capital (加华资本) for 4.20%. This values the company at over 7.1 billion yuan post-investment. Despite these injections, the Zheng family retains absolute control, necessitating transparency in governance practices to reassure investors during the Natural Hall IPO. The involvement of global players like L’Oréal could enhance credibility, but familial dominance remains a focal point for due diligence.
Strategic Implications for Investors
The Natural Hall IPO represents a test case for Chinese consumer brands transitioning to public markets. Key considerations include:
– Balancing growth aspirations with sustainable R&D investments to justify ‘tech beauty’ claims.
– Mitigating endorsement risks through diversified marketing approaches and robust crisis management.
– Enhancing governance structures to align with international standards, despite family oversight.
– Monitoring consumer sentiment and product safety records to preempt regulatory or reputational setbacks.
Investors should weigh these factors against Natural Hall’s market position and China’s cosmetics industry growth, projected to expand at a CAGR of 8% through 2028. The Natural Hall IPO could unlock value if management addresses these challenges proactively, but caution is warranted given the operational imbalances and external vulnerabilities highlighted in this analysis.